Medical device and MedTech insights, news, tips and more

Medtronic to buy Mazor Robotics for $1.64 Billion

September 21, 2018



Mazor Robotics Ltd., an Israeli biotech firm that develops robotic surgical systems, announced Friday it was being acquired by Irish-American medical device company Medtronic for a sum of $1.64 billion, the biggest-ever “exit” for an Israeli biotech company.

Medtronic previously owned an 11 percent stake in Mazor, which provides among its products a suite of software that includes image processing and computerized anatomy recognition. The technology enables preoperative planning, helping surgeons better plan spinal procedures.

Last year, Mazor, founded in 2001, received clearance from the US Food & Drug Administration for the Mazor X Align software to help surgeons correct spinal deformities. Medtronic was already the sole distributor of the software under an agreement between the two companies.

“We believe robotic-assisted procedures are the future of spine surgery, and provide surgeons a more precise, repeatable, and controlled ability to perform complex procedures,” said Geoff Martha, executive vice president of Medtronic and head of the company’s Restorative Therapies Group. “Medtronic is committed to accelerating the adoption of robotic-assisted surgery and transforming spine care through procedural solutions that integrate implants, biologics and enabling technologies.”

Of Mazor’s technology, Martha told Bloomberg, “It improves outcomes in spinal surgery and reduces the variability. Once we realized this is clearly the future, we knew we had to integrate all this technology.”

Martha said Medtronic aimed to expand Mazor’s operations in Israel.

“The acquisition of Mazor adds robotic-assisted guidance systems to our expanding portfolio of enabling technologies, and we intend to further cultivate Mazor’s legacy of innovation in surgical robotics with the site and team in Israel as a base for future growth.”

Medtronic began investing in Mazor in 2016.

Read More at the Source: In biggest-ever Israeli biotech exit, Medtronic buys Mazor for $1.6b | The Times of Israel

By: TOI Staff

A Speciality Recruiting Firm Exclusively Servicing The Medical Device Industry

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.



More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.